UPDATE: Magenta cuts 14% of staff, trims R&D amid tumultuous biotech marketsnews2022-04-14T14:10:48+00:00April 14th, 2022|FierceBiotech|
Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’news2022-04-14T13:39:58+00:00April 14th, 2022|FierceBiotech|
Editas brings on Sarepta CMO—for CEO swap, not the vacant CMO rolenews2022-04-14T12:55:57+00:00April 14th, 2022|FierceBiotech|
Merck’s next-gen pneumococcal vaccine receives FDA breakthrough status ahead of phase 3 trialnews2022-04-14T12:50:47+00:00April 14th, 2022|FierceBiotech|
Twist in Protagonist story as FDA seeks to rescind breakthrough nod ‘based on observed malignancies’news2022-04-14T10:17:26+00:00April 14th, 2022|FierceBiotech|
Chasing Roche, AbbVie posts data on CD20 blood cancer bispecific ahead of race to regulatorsnews2022-04-14T08:56:34+00:00April 14th, 2022|FierceBiotech|
CDx Biomarkers for Oncology Research & Developmentnews2022-04-13T15:33:43+00:00April 13th, 2022|FierceBiotech|
ProQR slashes 30% of workforce following phase 2/3 blundernews2022-04-13T14:51:00+00:00April 13th, 2022|FierceBiotech|
Cardiff Oncology’s chief medical officer exits after less than a yearnews2022-04-13T14:40:40+00:00April 13th, 2022|FierceBiotech|
Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinicnews2022-04-13T12:37:51+00:00April 13th, 2022|FierceBiotech|
